ValuEngine upgraded shares of Jazz Pharmaceuticals (NASDAQ:JAZZ) from a sell rating to a hold rating in a research report released on Tuesday, November 13th.
A number of other equities analysts also recently issued reports on the stock. BidaskClub downgraded shares of Jazz Pharmaceuticals from a buy rating to a hold rating in a report on Saturday, August 18th. Cantor Fitzgerald reissued a buy rating and issued a $201.00 price objective on shares of Jazz Pharmaceuticals in a report on Tuesday, November 6th. Piper Jaffray Companies set a $208.00 price objective on shares of Jazz Pharmaceuticals and gave the stock a buy rating in a report on Wednesday, November 7th. Wells Fargo & Co reissued a buy rating on shares of Jazz Pharmaceuticals in a report on Wednesday, November 7th. Finally, B. Riley lowered their price target on shares of Jazz Pharmaceuticals from $219.00 to $190.00 and set a buy rating on the stock in a report on Thursday, November 8th. Five analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. Jazz Pharmaceuticals presently has an average rating of Buy and a consensus target price of $189.76.
Shares of JAZZ stock traded down $1.15 during trading hours on Tuesday, reaching $143.50. The company had a trading volume of 1,117,908 shares, compared to its average volume of 522,401. Jazz Pharmaceuticals has a one year low of $130.15 and a one year high of $184.00. The firm has a market capitalization of $8.73 billion, a PE ratio of 15.01, a P/E/G ratio of 0.87 and a beta of 0.94. The company has a quick ratio of 4.16, a current ratio of 4.29 and a debt-to-equity ratio of 0.52.
Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its quarterly earnings results on Tuesday, November 6th. The specialty pharmaceutical company reported $3.58 EPS for the quarter, topping analysts’ consensus estimates of $3.32 by $0.26. Jazz Pharmaceuticals had a net margin of 28.09% and a return on equity of 24.92%. The firm had revenue of $469.37 million during the quarter, compared to analyst estimates of $482.64 million. During the same period in the previous year, the business posted $3.22 earnings per share. The business’s revenue for the quarter was up 14.0% on a year-over-year basis. Analysts anticipate that Jazz Pharmaceuticals will post 11.6 earnings per share for the current year.
In other news, CEO Bruce C. Cozadd sold 1,300 shares of the business’s stock in a transaction on Monday, October 1st. The shares were sold at an average price of $167.99, for a total value of $218,387.00. Following the transaction, the chief executive officer now owns 279,915 shares of the company’s stock, valued at $47,022,920.85. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Michael Patrick Miller sold 200 shares of the business’s stock in a transaction on Friday, September 14th. The stock was sold at an average price of $165.20, for a total transaction of $33,040.00. Following the completion of the transaction, the executive vice president now directly owns 25,372 shares in the company, valued at approximately $4,191,454.40. The disclosure for this sale can be found here. Insiders sold 6,600 shares of company stock worth $1,063,472 in the last three months. Insiders own 3.90% of the company’s stock.
Hedge funds have recently added to or reduced their stakes in the company. C WorldWide Group Holding A S increased its position in Jazz Pharmaceuticals by 0.7% in the third quarter. C WorldWide Group Holding A S now owns 49,935 shares of the specialty pharmaceutical company’s stock worth $8,396,000 after purchasing an additional 343 shares during the last quarter. Tdam USA Inc. increased its position in Jazz Pharmaceuticals by 14.8% in the second quarter. Tdam USA Inc. now owns 2,818 shares of the specialty pharmaceutical company’s stock worth $486,000 after purchasing an additional 363 shares during the last quarter. Adell Harriman & Carpenter Inc. increased its position in Jazz Pharmaceuticals by 3.0% in the second quarter. Adell Harriman & Carpenter Inc. now owns 13,790 shares of the specialty pharmaceutical company’s stock worth $2,376,000 after purchasing an additional 400 shares during the last quarter. GAM Holding AG increased its position in Jazz Pharmaceuticals by 1.1% in the second quarter. GAM Holding AG now owns 38,733 shares of the specialty pharmaceutical company’s stock worth $6,674,000 after purchasing an additional 433 shares during the last quarter. Finally, Nelson Van Denburg & Campbell Wealth Management Group LLC increased its position in Jazz Pharmaceuticals by 28.2% in the second quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 2,139 shares of the specialty pharmaceutical company’s stock worth $369,000 after purchasing an additional 470 shares during the last quarter. 91.53% of the stock is currently owned by hedge funds and other institutional investors.
Jazz Pharmaceuticals Company Profile
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.
Recommended Story: Fundamental Analysis and Choosing Stocks
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.